- Home
- SNDX
as 07-26-2024 3:36pm EST
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Syndax Pharmaceuticals Inc. SNDX prepares to release earnings report on 01 Aug 2024.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.6B | IPO Year: | 2016 |
| Target Price: | $34.56 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.22 - $25.34 | Next Earning Date: | 08-01-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 248.23% |
Stock Insider Trading Activity of Syndax Pharmaceuticals Inc. (SNDX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goldan Keith A. | SNDX | Chief Financial Officer | Jun 14 '24 | Buy | $20.03 | 1,250 | $25,037.25 | 52,623 | SEC Form 4 |
Latest Syndax Pharmaceuticals Inc. News
SNDX Breaking Stock News: Dive into SNDX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
PR Newswire
2 days ago
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
Zacks
17 days ago
Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
PR Newswire
21 days ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MT Newswires
a month ago
Jefferies Initiates Syndax Pharmaceuticals at Buy With $37 Price Target
MT Newswires
a month ago
Stifel Raises Price Target on Syndax Pharmaceuticals to $42 From $40, Maintains Buy Rating
PR Newswire
a month ago
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
GlobeNewswire
2 months ago
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
Compare SNDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.